Iakov I. Davydov
Research Subjects
Iakov I. Davydov has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Marbach
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
33 shared publications - Christian Heichinger
18Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
32 shared publications - Christine McIntyre
19Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom
31 shared publications - Christoph Markert
23Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich, Munich, Germany
31 shared publications - Dominik Kraus
18Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
31 shared publications - Francesca Michielin
18Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
31 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Baseline immune cell subset associations with objective response rate
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Baseline immune cell subset associations with objective response rate
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Kaplan-Meier plots for baseline immunohistochemistry biomarker associations
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Kaplan-Meier plots for baseline immunohistochemistry biomarker associations
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Baseline prevalence and clinical response associations in immune cell subsets
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Baseline prevalence and clinical response associations in immune cell subsets
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Association between ctDNA and clinical response
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Association between ctDNA and clinical response
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Longitudinal analysis of regulatory T-cell dynamics following tobemstomig or nivolumab treatment
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Longitudinal analysis of regulatory T-cell dynamics following tobemstomig or nivolumab treatment
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Baseline tissue gene expression and gene signature associations with clinical outcomes
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Baseline tissue gene expression and gene signature associations with clinical outcomes
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Immunohistochemistry and immunofluorescent assay details
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Immunohistochemistry and immunofluorescent assay details
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Response assessment according to RECIST version 1.1
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Response assessment according to RECIST version 1.1